Get the Stockscreener App
26.99
0.78%
0.21
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Fisher Asset Management LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Decreases Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Participation in Jefferies London H - GuruFocus.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Jennison Associates LLC - MarketBeat
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Quest Partners LLC Increases Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $53.67 - MarketBeat
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - MSN
Finansavisen - Finansavisen
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat
Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma
IDEAYA Biosciences Taps Former Gilead Oncology VP as Chief Commercial Officer | IDYA Stock News - StockTitan
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India
500: Something went wrong - Investing.com Canada
Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK
Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com
IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia
FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com
(IDYA) Investment Analysis - Stock Traders Daily
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day – Company Announcement - Financial Times
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve
Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online
IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media
Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat
90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat
The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St
Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat
FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat
Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
/C O R R E C T I O N — IDEAYA Biosciences, Inc./ - Morningstar
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):